-
1.发明申请公开(公告)号：US20160339065A1
公开(公告)日：2016-11-24
申请号：US15161654
申请日：2016-05-23
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo LLC
发明人： James ADAMS , Rosa KRAJMALIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
IPC分类号： A61K35/741 , A61K38/08 , A61K45/06
CPC分类号： A61K38/08 , A61K35/74 , A61K38/14 , A61K45/06 , A61K2035/128 , A61K2300/00
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
摘要翻译： 本公开涉及通过恢复ASD患者的肠道微生物群来治疗自闭症谱系障碍（ASD）的组合物和方法。 这些方法可以与ASD患者一起使用，无论是否有持续的胃肠道症状。 这里提供了一种在有需要的受试者中进行ASD治疗的方法，其包括或基本上由给予受试者的包含粪便微生物或粪便微生物群制剂的治疗组合物组成。 这里还提供了一种方法，包括向人受试者施用抗生素; 使人类受试者进行肠道清洁; 并向人类受试者施用纯化的粪便微生物群。 进一步提供了这里描述的治疗后患者症状改善的评估和定量表征。
-
公开(公告)号：US20220088089A1
公开(公告)日：2022-03-24
申请号：US17539767
申请日：2021-12-01
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Finch Therapeutics Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
IPC分类号： A61K35/741 , A61K45/06 , A61K38/08 , A61K38/14 , A61K35/74
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20200061148A1
公开(公告)日：2020-02-27
申请号：US16548404
申请日：2019-08-22
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20190328825A1
公开(公告)日：2019-10-31
申请号：US16510506
申请日：2019-07-12
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20190134144A1
公开(公告)日：2019-05-09
申请号：US16235635
申请日：2018-12-28
申请人： Arizona Board of Regents on behalf of Arizona State University , Regents of the University of Minnesota , Crestovo Holdings LLC
发明人： James ADAMS , Rosa KRAJMALNIK-BROWN , Dae-Wook KANG , Michael J. SADOWSKY , Alexander KHORUTS , Thomas J. BORODY
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.
-
公开(公告)号：US20190134111A1
公开(公告)日：2019-05-09
申请号：US16306240
申请日：2017-06-14
IPC分类号： A61K35/741 , A61K35/74 , A61K35/745
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.
-
公开(公告)号：US20170360848A1
公开(公告)日：2017-12-21
申请号：US15290798
申请日：2016-10-11
IPC分类号： A61K35/741 , A61K35/74
CPC分类号： A61K35/741 , A61K35/74 , A61K35/745
摘要： The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more gut microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.
-
公开(公告)号：US20240293476A1
公开(公告)日：2024-09-05
申请号：US18652238
申请日：2024-05-01
IPC分类号： A61K35/74
CPC分类号： A61K35/74
摘要： The present disclosure relates to methods and compositions suitable for changing metabolite levels in a subject in need thereof. In particular, this application provides methods and compositions for changing metabolite levels in a subject diagnosed with Autism Spectrum Disorder (ASD). Methods of preventing or treating an ASD in a subject thereof, as well as methods of selecting a treatment plan for treating an ASD in a subject are also provided.
-
公开(公告)号：US20200061127A1
公开(公告)日：2020-02-27
申请号：US16348425
申请日：2017-11-10
IPC分类号： A61K35/74
摘要： The present disclosure relates to methods and compositions suitable for changing metabolite levels in a subject in need thereof. In particular, this application provides methods and compositions for changing metabolite levels in a subject diagnosed with Autism Spectrum Disorder (ASD). Methods of preventing or treating an ASD in a subject thereof, as well as methods of selecting a treatment plan for treating an ASD in a subject are also provided.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.033 秒)
